Slides on Key Decisions in HIV Care: Treatment Considerations for Transgender PWH

Learn some of the key considerations for ART management for transgender PWH including providing care within a gender-affirmative care model, considering drug-drug interactions between hormone therapy and ART, and addressing barriers to engagement and retention in care.
Michelle D. Collins-Ogle, MD, FAAP, FPIDS, AAHIVS
Format: Microsoft PowerPoint (.ppt)
File Size: 206 KB
Released: April 29, 2022

Acknowledgements

Educational grant provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Related Content

Clinical Care Options (CCO) slideset providing expert insights for ART management in complex clinical situations, including extensive previous treatment

Joseph J. Eron, Jr., MD
Program Director
Jeffrey Kwong, DNP, MPH, FAANP, FAAN
Program Director
Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP
Program Director
Eric S. Daar, MD
Released: July 1, 2022

person default Ariel Campos, MD person default Alicia Piñeirúa Menéndez, MD, MPH Leticia M. Pérez Saleme, MD Luis E. Soto-Ramirez, MD Released: June 30, 2022

Clinical Care Options (CCO): South African patient’s perspective on living a full life with her HIV diagnosis, long-term ART, and HIV activism

person default Yvette Raphael Released: June 21, 2022

Expert HIV faculty analyze new data from CROI 2022, from Clinical Care Options (CCO)

Joseph J. Eron, Jr., MD
Program Director
Jeffrey Kwong, DNP, MPH, FAANP, FAAN
Program Director
Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP
Program Director
Gregory Huhn, MD, MPHTM Daniel R. Kuritzkes, MD Babafemi Taiwo, MBBS
Physicians: maximum of 1.25 AMA PRA Category 1 Credits Registered Nurses: 1.25 Nursing contact hours Pharmacists: 1.25 contact hours (0.125 CEUs) Released: June 17, 2022 Expired: June 16, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings